Q4 2025 Guardant Health Inc Earnings Call Transcript
Key Points
- Guardant Health Inc (GH) reported a 39% year-over-year revenue growth in Q4 2025, reaching $281 million, and a 33% growth for the full year, totaling $982 million.
- The company's Oncology business saw a 30% increase in revenue to $190 million, with oncology volumes growing 38% to approximately 79,000 tests in Q4.
- Guardant360 Liquid volumes increased nearly 30%, supported by expanding clinical utility from Smart apps launched over the past year.
- The Shield product line delivered $35 million in Q4 revenue, driven by approximately 38,000 tests, marking a significant increase from 24,000 tests in Q3.
- Non-GAAP gross margin improved to 66% in Q4, up from 63% in the prior year, driven by cost reductions and operational efficiencies.
- Despite strong growth, the company continues to experience significant cash burn, with a free cash flow burn of $233 million for the year.
- The Shield ASP is expected to decline in 2026 due to a mix shift towards non-Medicare patients, impacting overall profitability.
- The company anticipates continued high investment in the screening business, with a similar level of cash burn as in 2025, around $220 million.
- There is uncertainty regarding the timing and impact of potential FDA approval for Guardant360 Liquid CDx, which could affect future revenue projections.
- The company faces challenges in achieving reimbursement for concurrent ordering of tissue and blood tests, which could limit growth in the tissue business.
Good afternoon. Thank you for attending the Guardant Health Q4 2025 Earnings Call. My name is Cameron, and I'll be your moderator for today. (Operator Instructions)
I would now like to pass the conference over to your host, Zarak Khurshid, VP of Investor Relations. You may proceed.
Thank you. Earlier today, Guardant Health released financial results for the quarter and year ended December 31, 2025. Joining me today from Guardant are Helmy Eltoukhy, Co-CEO; AmirAli Talasaz, Co-CEO; and Mike Bell, Chief Financial Officer. Before we begin, I'd like to remind you that during this call, management will make forward-looking statements within the meaning of Federal Securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated.
This call will also include a discussion of non-GAAP financial measures, which are adjusted to exclude certain specified items. Additional information
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
